Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.1519
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 199099568700.0
- FreeCF/Share 6.7321
- PFCF 11.6849
- PE 11.511
- Debt/Assets 0.3027
- DivYield 0.0404
- ROE 0.3816
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Read More
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Published: June 13, 2025 by: Investopedia
Sentiment: Positive
Merck (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda.
Read More
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
Published: June 12, 2025 by: Reuters
Sentiment: Neutral
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court records show.
Read More
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
Read More
Drug pricing reform talks with US government lack clarity, industry executives say
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.
Read More
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 10:00 AM ET Company Participants Dean Y. Li - Executive VP & President of Merck Research Laboratories Robert M.
Read More
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Positive
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YCharts 6/6/25 data on Dividends from 78, which hereafter are referred to as the Fortune Return on Leadership Dividend Dogs (FROLD). ReturnOnLeadership is based on four fundamental factors: Connection to Purpose, Strategic Clarity, Leadership Alignment, and Focused Action.
Read More
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.
Read More
Will Merck's Keytruda Continue to Drive Growth Amid Looming LOE?
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK leans on Keytruda for growth as exclusivity loss nears, with new combos and launches aiming to ease reliance.
Read More
Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee
Published: June 10, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Angelica Peebles reports on news regarding vaccines.
Read More
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstaZeneca
Published: June 09, 2025 by: CNBC
Sentiment: Positive
The Food and Drug Administration approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter.
Read More
U.S. FDA Approves Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Published: June 09, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves Merck's ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season.
Read More
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Published: June 09, 2025 by: Benzinga
Sentiment: Positive
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Read More
Is Merck Stock About To Crash?
Published: June 03, 2025 by: Forbes
Sentiment: Negative
Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average revenue growth compared to J&J's modest 4%, and Merck's operating cash flow margins are a healthier 33% versus J&J's 28%.
Read More
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Published: June 02, 2025 by: CNBC Television
Sentiment: Neutral
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Read More
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck reports promising response rates for its ADC zilovertamab vedotin in relapsed DLBCL and KRAS inhibitor MK-1084 in solid tumors.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
Merck Stock's Ticking Keytruda Time Bomb
Published: June 02, 2025 by: Forbes
Sentiment: Negative
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.
Read More
2 Dirt Cheap Dividend Stocks That Are Practically Giving Themselves Away
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
Even pros can't beat the market. Forecasts fail, fees pile up, and short-term thinking hurts returns. So I stick to quality dividend stocks. I found two high-conviction dividend stocks that the market is underpricing. Both offer strong income and long-term upside if my thesis plays out. They aren't perfect, but that's where the opportunity lies. I believe the market's pessimism is overdone, and the reward outweighs the risk.
Read More
Top 10 High-Yield Dividend Stocks
Published: June 01, 2025 by: Seeking Alpha
Sentiment: Positive
The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superior dividend yield. The June 2025 watchlist includes 10 stocks with an average forward dividend yield of 3.62% and an expected return of 13.63%.
Read More
Merck & Co., Inc. (MRK) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Bernstein 41st Annual Strategic Decisions Conference May 29, 2025 3:30 PM ET Corporate Participants Rob Davis - Chairman and Chief Executive Officer Dean Li - Executive Vice President, President of Merck Research Labs Conference Call Participants Courtney Breen - Bernstein Courtney Breen All right. So, we might kick off our conversation with Merck today.
Read More
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Merck Proves Why It's Still A Top Pharma Pick
Published: May 27, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a catastrophic drop in sales of the Gardasil franchise, mainly due to weak demand from China, Merck once again beat consensus EPS and revenue estimates. So, the key contributors whose performance pleasantly surprised me in Q1 2025, and thanks to which Merck's operating income margin remains above 40%, are Vaxneuvance, Winrevair, and Welireg. From its oncology franchise, I highlight Welireg as a 'gem,' whose sales amounted to $137 million in the first three months of 2025, an increase of 61.2% year-on-year.
Read More
Merck Announces Third-Quarter 2025 Dividend
Published: May 27, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Third-Quarter 2025 Dividend.
Read More
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock?
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck stock lags industry as Keytruda dependency, Gardasil woes in China, and tariff risks cloud outlook despite pipeline strength and new launches.
Read More
Should You Buy MRK Stock At $80?
Published: May 26, 2025 by: Forbes
Sentiment: Negative
Merck (NYSE:MRK) stock has experienced a significant 22% decline this year, sharply underperforming the broader S&P 500 index, which is down only 1%. This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term growth prospects of its blockbuster drugs, Keytruda and Gardasil.
Read More
Merck: Defensive Yield Meets Long-Term Optionality
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Positive
The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology, and vaccines through acquisitions and R&D, offering long-term optionality beyond Keytruda. Gardasil's China-driven slump has limited downside left, with stable ex-China growth and male-use approval offering medium-term recovery potential.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert M. Davis J.D.
- Employees 73000